{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:31:08Z","timestamp":1781325068693,"version":"3.54.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>A growing number of evidence have demonstrated the involvement of enhancer RNAs (eRNAs) in tumor progression. However, the possible functions of eRNAs in hepatocellular carcinoma (HCC) remain largely unclear. Our present research aimed to screen critical eRNAs and to further delve into the clinical significance of eRNAs in HCC patients. In this study, we identified 124 prognosis-related eRNAs by analyzing The Cancer Genome Atlas (TCGA) datasets. Among them, SPRY4 antisense RNA 1 (SPRY4-AS1) may be a key eRNA involved in HCC progression. SPRY4 was a regulatory target of SPRY4-AS1. High SPRY4-AS1 expression was associated with poor prognosis of HCC patients. Kyoto Encyclopedia of Genes and Genomes (KEGG) assays revealed that the mainly enriched biological process included Human papillomavirus infection, Hippo signaling pathway, and Proteoglycans in cancer. Besides, RT-PCR and immunohistochemical staining confirmed SPRY4-AS1 as an overexpressed eRNA in HCC specimens. The pan-cancer assays revealed that SPRY4-AS1 was associated with glioblastoma multiforme (GBM), adrenocortical carcinoma (ACC), brain lower grade glioma (LGG) and mesothelioma(MESO). Positive associations were observed between SPRY4-AS1 and SPRY4 (its target gene) in 16 tumor types. Collectively, our findings reveal a novel eRNA SPRY4-AS1 for HCC progression and suggest that SPRY4-AS1 may be a potential biomarker and therapeutic target for HCC.<\/jats:p>","DOI":"10.3389\/fonc.2021.765484","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T07:27:40Z","timestamp":1633332460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["SPRY4-AS1, A Novel Enhancer RNA, Is a Potential Novel Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Mu","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-bo","family":"Qie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-long","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer Statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.4334","article-title":"Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China","volume":"154","author":"Xu","year":"2019","journal-title":"JAMA Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.suronc.2016.03.002","article-title":"Hepatocellular Carcinoma: From Diagnosis to Treatment","volume":"25","author":"Grandhi","year":"2016","journal-title":"Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2017.10.007","article-title":"Hepatocellular Carcinoma in the Era of Immunotherapy","volume":"42","author":"Sim","year":"2018","journal-title":"Curr Problems Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01105","article-title":"Mechanisms of RNA N(6)-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology","volume":"10","author":"Lu","year":"2020","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/cells9061370","article-title":"Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment","volume":"9","author":"Pi\u00f1ero","year":"2020","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.017","article-title":"Advances in Molecular Classification and Precision Oncology in Hepatocellular Carcinoma","volume":"72","author":"Rebouissou","year":"2020","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2016.10.006","article-title":"Alpha-Foetoprotein (AFP): A Multi-Purpose Marker in Hepatocellular Carcinoma","volume":"463","author":"Sauzay","year":"2016","journal-title":"Clinica chimica acta; Int J Clin Chem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","article-title":"Functional Classification and Experimental Dissection of Long Noncoding RNAs","volume":"172","author":"Kopp","year":"2018","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-0446-0","article-title":"Enhancer RNAs are an Important Regulatory Layer of the Epigenome","volume":"27","author":"Sartorelli","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gad.311605.118","article-title":"Enhancer Transcription: What, Where, When, and Why","volume":"32","author":"Tippens","year":"2018","journal-title":"Genes Dev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2017.1353862","article-title":"eRNA Binding Produces Tailored CBP Activity Profiles to Regulate Gene Expression","volume":"14","author":"Bose","year":"2017","journal-title":"RNA Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1042\/EBC20200014","article-title":"Enhancer RNA: Biogenesis, Function, and Regulation","volume":"64","author":"Ye","year":"2020","journal-title":"Essays Biochem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4161\/epi.26942","article-title":"RNA-Mediated Gene Activation","volume":"9","author":"Jiao","year":"2014","journal-title":"Epigenetics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01307","article-title":"From Super-Enhancer Non-Coding RNA to Immune Checkpoint: Frameworks to Functions","volume":"9","author":"Wu","year":"2019","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1038\/s41467-019-12543-5","article-title":"Transcriptional Landscape and Clinical Utility of Enhancer RNAs for eRNA-Targeted Therapy in Cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.607636","article-title":"Long Non-Coding RNA SNHG17 Upregulates RFX1 by Sponging miR-3180-3p and Promotes Cellular Function in Hepatocellular Carcinoma","volume":"11","author":"Ma","year":"2020","journal-title":"Front Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: New Perspectives on Genomes, Pathways, Diseases and Drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3715","article-title":"Toward Understanding the Origin and Evolution of Cellular Organisms","volume":"28","author":"Kanehisa","year":"2019","journal-title":"Protein Sci Publ Protein Soc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13046-019-1455-x","article-title":"Interleukin-8 Promotes Integrin \u03b23 Upregulation and Cell Invasion Through PI3K\/Akt Pathway in Hepatocellular Carcinoma","volume":"38","author":"Sun","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.01.014","article-title":"Advances in the Early Diagnosis of Hepatocellular Carcinoma","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01316","article-title":"New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1073274817729240","DOI":"10.1177\/1073274817729240","article-title":"The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer","volume":"24","author":"Shiani","year":"2017","journal-title":"Cancer control J Moffitt Cancer Center"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-020-02470-1","article-title":"Critical Review of HCC Imaging in the Multidisciplinary Setting: Treatment Allocation and Evaluation of Response","volume":"45","author":"Amorim","year":"2020","journal-title":"Abdominal Radiol (New York)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for Cancer Therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11523-012-0212-2","article-title":"A Review on Various Targeted Anticancer Therapies","volume":"7","author":"Li","year":"2012","journal-title":"Targeted Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.7150\/thno.29678","article-title":"Circular RNAs in Immune Responses and Immune Diseases","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00041.2015","article-title":"Non-Coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches","volume":"96","author":"Beermann","year":"2016","journal-title":"Physiol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20204008","article-title":"FOXP4-AS1 is a Favorable Prognostic-Related Enhancer RNA in Ovarian Cancer","volume":"41","author":"Hua","year":"2021","journal-title":"Bioscience Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.607740","article-title":"CRISPR-Cas13a Targeting the Enhancer RNA-SMAD7e Inhibits Bladder Cancer Development Both In Vitro and In Vivo","volume":"7","author":"Che","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202151","article-title":"Downregulation of Enhancer RNA EMX2OS is Associated With Poor Prognosis in Kidney Renal Clear Cell Carcinoma","volume":"12","author":"Jiang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI88486","article-title":"Hippo Signaling Interactions With Wnt\/\u03b2-Catenin and Notch Signaling Repress Liver Tumorigenesis","volume":"127","author":"Kim","year":"2017","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cancers10040094","article-title":"The Hippo Pathway: Immunity and Cancer","volume":"10","author":"Taha","year":"2018","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.46091","article-title":"Retinal Dehydrogenase 5 (RHD5) Attenuates Metastasis via Regulating HIPPO\/YAP Signaling Pathway in Hepatocellular Carcinoma","volume":"17","author":"Hu","year":"2020","journal-title":"Int J Med Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30930","article-title":"PDLIM1 Inhibits Tumor Metastasis Through Activating Hippo Signaling in Hepatocellular Carcinoma","volume":"71","author":"Huang","year":"2020","journal-title":"Hepatol (Baltimore Md)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.765484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T07:27:43Z","timestamp":1633332463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.765484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":35,"alternative-id":["10.3389\/fonc.2021.765484"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.765484","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"article-number":"765484"}}